RECIST、iRECIST与PERCIST评估非小细胞肺癌PD-1/PD-L1阻断治疗疗效的比较
结果显示RECIST 1.1与PERCIST 1.0反应分类在6例(14.2%;κ=0.581)患者中不一致,RECIST 1.1与iRECIST在2例假性进展患者中不一致;三种标准下应答者中位无进展生存期和总生存期均显著长于非应答者(P<0.001),三种标准间无显著差异(P>0.05)。
要点
- RECIST 1.1与PERCIST 1.0仅中等一致(κ=0.581),6例(14.2%)分类不一致。
- RECIST 1.1与iRECIST在2例假性进展患者中分类不一致。
- 三种标准下应答者PFS和OS均显著优于非应答者(P<0.001)。
核心结论
- RECIST 1.1与PERCIST 1.0仅呈中等一致性,但两者均可预测PD-1/PD-L1抑制剂治疗的疗效反应。
- 出现假性进展时,代谢肿瘤活性可能有助于正确分类治疗反应。
研究设计与样本
- 前瞻性研究,纳入42例接受PD-1/PD-L1抑制剂治疗的晚期非小细胞肺癌患者,经机构审查委员会批准且所有患者签署书面知情同意。
- 采用Cohen κ和Wilcoxon符号秩检验评估各标准间一致性,采用Kaplan-Meier估计无进展生存期和总生存期。
主要发现
- RECIST 1.1与PERCIST 1.0反应分类在6例患者中不一致(14.2%;κ=0.581)。
- RECIST 1.1与iRECIST在2例治疗开始后出现假性进展的患者中不一致。
- 三种标准下应答者较非应答者的中位无进展生存期和总生存期均显著更长(P<0.001),三种标准间无显著差异(P>0.05)。
关键数值与推荐
- RECIST 1.1与PERCIST 1.0不一致6例(14.2%),κ=0.581。
- RECIST 1.1与iRECIST不一致2例,均为治疗开始后假性进展者。
- 三种标准下应答者与非应答者PFS及OS比较均P<0.001,三种标准间比较P>0.05。
临床怎么用
- 对接受PD-1/PD-L1抑制剂治疗的晚期非小细胞肺癌患者,可用RECIST 1.1或PERCIST 1.0评估疗效反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to compare the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the immune RECIST (iRECIST) criteria, and the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) 1.0 in patients with advanced non-small cell lung cancer treated with programmed cell death protein 1 (PD-1)/programmed cell death protein 1 ligand (PD-L1) inhibitors. METHODS: This prospective study of 42 patients treated with a PD-1/PD-L1 inhibitor was approved by our institutional review board, and all patients gave written, informed consent. Tumor burden dynamics were assessed on F-FDG PET/CT before and after treatment initiation. Immunotherapeutic responses were evaluated according to RECIST 1.1, iRECIST, and PERCIST 1.0 for the dichotomous groups, responders versus nonresponders. Cohen κ and Wilcoxon signed rank tests were used to evaluate concordance among these criteria. We assessed progression-free survival and overall survival using the Kaplan-Meier estimator. RESULTS: The RECIST 1.1 and PERCIST 1.0 response classifications were discordant in 6 patients (14.2%; κ = 0.581). RECIST 1.1 and iRECIST were discordant in 2 patients, who evidenced pseudoprogression after treatment initiation. Median progression-free survival, as well as overall survival, was significantly longer for responders compared with nonresponders for all criteria (P < 0.001), with no significant difference between the 3 criteria (P > 0.05). CONCLUSIONS: RECIST 1.1 and PERCIST 1.0 show only moderate agreement, but both can predict treatment response to PD-1/PD-L1 inhibitor therapy. In case of pseudoprogression, metabolic tumor activity may help to correctly classify treatment response.
引用
- Beer L, Hochmair M, Haug AR, et al. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer. Clin Nucl Med. 2019. PMID: 31021918. doi:10.1097/RLU.0000000000002603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。